Related Experiment Video
Updated: Aug 9, 2025
Determination of the Relative Cell Surface and Total Expression of Recombinant Ion Channels Using Flow Cytometry
Published on: September 28, 2016
Structure-Function Studies of Sponge-Derived Compounds on the Cardiac CaV3.1 Channel
Anne-Sophie Depuydt1, Piyush A Patel2, Žan Toplak3
1Toxicology and Pharmacology, Campus Gasthuisberg, University of Leuven, Onderwijs en Navorsing 2, Herestraat 49, P.O. Box 922, 3000 Leuven, Belgium.
Insights
Marine sponge alkaloids, purpurealidin analogs, were identified as novel inhibitors of T-type calcium (CaV3) channels. These compounds show potential for treating heart conditions by blocking ion flow in CaV3.1 channels.
Area of Science:
- Cardiovascular Pharmacology
- Ion Channel Modulation
- Marine Natural Products Chemistry
Background:
- T-type calcium (CaV3) channels are crucial for cardiac function, with their role amplified in heart failure.
- Current therapeutic options for modulating CaV3 channels are limited, highlighting the need for novel inhibitors.
Purpose of the Study:
- To discover and characterize novel inhibitors of T-type calcium channels using purpurealidin analogs.
- To investigate the structure-activity relationships of purpurealidin analogs for CaV3.1 channel inhibition.
- To elucidate the mechanism of action of potent purpurealidin analogs.
Main Methods:
- Electrophysiological investigation of rat CaV3.1 channels using 119 purpurealidin analogs.
- Structure-activity relationship (SAR) studies to identify key structural features for inhibition.
- Mechanism of action studies, including activation curve analysis and selectivity screening against hERG channels.
Main Results:
- Purpurealidin I and 119 analogs were evaluated; analogs 74, 76, 79, and 99 demonstrated potent CaV3.1 inhibition (IC50 ≈ 3 μM).
- No shift in activation curves indicated a pore-blocking mechanism, obstructing ion flow through the CaV3.1 channel.
- Selectivity screening revealed activity on hERG channels, suggesting potential off-target effects.
Conclusions:
- A novel class of T-type calcium channel inhibitors, derived from purpurealidin alkaloids, has been identified.
- SAR studies provide valuable insights for the rational design of synthetic CaV3 channel modulators.
- Further research is needed to optimize selectivity and assess in vivo efficacy and safety.
Abstract:
T-type calcium (CaV3) channels are involved in cardiac automaticity, development, and excitation-contraction coupling in normal cardiac myocytes. Their functional role becomes more pronounced in the process of pathological cardiac hypertrophy and heart failure. Currently, no CaV3 channel inhibitors are used in clinical settings. To identify novel T-type calcium channel ligands, purpurealidin analogs were electrophysiologically investigated. These compounds are alkaloids produced as secondary metabolites by marine sponges, and they exhibit a broad range of biological activities. In this study, we identified the inhibitory effect of purpurealidin I (1) on the rat CaV3.1 channel and conducted structure-activity relationship studies by characterizing the interaction of 119 purpurealidin analogs. Next, the mechanism of action of the four most potent analogs was investigated. Analogs 74, 76, 79, and 99 showed a potent inhibition on the CaV3.1 channel with IC50's at approximately 3 μM. No shift of the activation curve could be observed, suggesting that these compounds act like a pore blocker obstructing the ion flow by binding in the pore region of the CaV3.1 channel. A selectivity screening showed that these analogs are also active on hERG channels. Collectively, a new class of CaV3 channel inhibitors has been discovered and the structure-function studies provide new insights into the synthetic design of drugs and the mechanism of interaction with T-type CaV channels.
Related Concept Videos
01:26Voltage-gated Ion Channels
Generally, all voltage-gated ion channels have a 'voltage-sensing domain' that spans the lipid bilayer. The charged residues in the sensor move in response to the membrane potential changes that open the channel allowing ions movement. There are several...
01:18Patch Clamp
In this method, a glass micropipette containing electrolyte solution is tightly sealed against a small portion of the cell membrane. As a result, a patch of the cell...
01:12Mechanically-gated Ion Channels
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:19Ion Channels
Ion channels are specialized integral membrane proteins on the plasma membrane that allow...